Abstract 1626MO
Background
Palliative chemotherapy is the mainstay of treatment for patients with advanced soft tissue sarcomas (STS), however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and preferences -though understudied- are central to treatment decisions. Our objectives were to explore priorities for quality versus quantity (length) of life (QoL vs. LoL) and treatment expectations in patients starting chemotherapy (CTx).
Methods
The HOLISTIC study is an international prospective cohort study assessing health-related quality of life in advanced STS patients receiving palliative CTx. Participants completed a baseline questionnaire before starting 1st-line CTx, including treatment expectations and preferences for QoL vs. LoL. Chi-squared and Fisher’s exact tests were used to evaluate associations between patient characteristics, preferences and expectations.
Results
In total, 137 patients with advanced STS participated (U.K: n=72, Netherlands: n=65). Median age was 62 years (range 27-79). Preference for extended LoL (48%) was slightly more common than preference for QoL (41%); 9% valued LoL and QoL equally. Younger patients (aged<40 years; P=0.002) and those who were employed (P=0.019) prioritised LoL. U.K participants and those with dependent children tended to prioritise LoL, however, this trend was not statistically significant. Most patients thought that CTx would help them to live longer (88%), 27% believed CTx was potentially curative and 67% thought that it would improve cancer-related problems. Belief that treatment could be curative was more common among ‘non-Caucasian’ participants (n=22; P=0.016). Gender, marital status, education level, performance status, baseline health-related quality of life, disease extent and time period since advanced STS diagnosis were not associated with preferences or expectations.
Conclusions
These data show heterogenous preferences and expectations among advanced STS patients starting 1st line chemotherapy, supporting personalised decision making. Treatment regret will be a topic of further study.
Clinical trial identification
NCT03621332.
Editorial acknowledgement
Legal entity responsible for the study
Royal Marsden NHS Foundation Trust and Institute of Cancer Research.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1624MO - Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Presenter: Javier Martin Broto
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Presenter: Emanuela Palmerini
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1627MO - Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network
Presenter: Anna Maria Frezza
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1628MO - A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1629MO - First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Presenter: Silvia Stacchiotti
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Jean-Yves Blay
Session: Mini Oral - Sarcoma
Resources:
Slides
Webcast
Invited Discussant 1621MO, 1622MO and 1623MO
Presenter: Jean-Yves Blay
Session: Mini Oral - Sarcoma
Resources:
Slides
Webcast